Research groups
Neuroimmune-pharmacology Research Group
Erika Pintér (professor) E-mail:
Tel.: +36 (72) 536-000 (ext: 35097, 36217)
Research interest

The research group investigates the neuroimmune interactions in different acute and chronic inflammatory reactions, as well as in degenerative disorders.  The main areas of research are the next:

Investigation of the role of TRPA1 in neurodegenerative disease. Interactions between neurons and glial cells (astrocytes, microglia and oligodendrocytes) in mouse models of multiple sclerosis and Alzheimer’ disease. (PI: Dr. Kata Bölcskei)

Examination of the role of TRP channels in different skin conditions with special interest of allergic contact dermatitis and psoriasis using pharmacological and genetic tools. (PI: Dr. Ágnes Kemény)

The pharmacoinformatics research is focused on the development and applications of computer-aided tools of rational, target-based design. They are actively engaged in computational docking, molecular dynamics and other methods which can predict the atomic resolution structure and strength of target-ligand interactions.     (PI: Dr. Csaba Hetényi)

Investigating biological effects and functions of hydrogen sulfide, sodium polysulfide and dimethyl trisulfide with special emphasis on transient receptor potential ankyrin 1 (TRPA1) ion channel-mediated ones. (PI: Dr. Gabor Pozsgai)

Support of the research with the methods molecular genetics. Cloning of TRPV1, TRPA1 és SSTR1-5 receptors. Producing TRPV1, TRPA1 and SSTR1-5 receptor expressing cell lines. Execution of fluorescent and radioactive binding studies, producing conditional knock out animals. (PI: Dr. Zoltán Sándor)

AtheNA LUMINEX 100 (Luminex Corp.)
CyFlow Space flow citométer (Partec)
Fluoreszcens molekuláris tomográf
HPLC készülék
Luminex multiplex citokin-meghatározásra alkalmas készülék
Olympus BX-51 mikroszkóp DP-50 kamerával
Skyscan micro CT készülék
Szcintillációs Beta-számláló (Packard Tri-Carb 2800 TR)
Representative publications
A CRPS-IgG-transfer-trauma model reproducing inflammatory and positive sensory signs associated with complex regional pain syndrome. Tekus V., Hajna Zs., Borbely E., Markovics A., Bagoly T., Szolcsanyi J., Thompson V., Kemeny A., Helyes Zs., Goebel A.
Pain (2014/155(2): 299-308.)
DOI | PubMed | Scopus
Capsaicin-sensitive sensory nerves exert complex regulatory functions in the serum-transfer mouse model of autoimmune arthritis. Borbely E., Botz B., Bolcskei K., Kenyer T., Kereskai L., Kiss T., Szolcsanyi J., Pinter E., Csepregi J.Z., Mocsai A., Helyes Z.
Brain, Behavior, and Immunity (2015/45: 50-59.)
DOI | PubMed | Scopus
Hemokinin-1 mediates anxiolytic and anti-depressant-like actions in mice. Borbely E., Hajna Z., Nabi L., Scheich B., Tekus V., Laszlo K., Ollmann T., Kormos V., Gaszner B., Karadi Z., Lenard L., Paige C.J., Quinn J.P., Szolcsanyi J., Pinter E., Keeble J., Berger A., Helyes Z.
Brain, Behavior, and Immunity (2017/59: 219-232. )
DOI | PubMed | Scopus
Somatostatin receptor subtype 4 activation is involved in anxiety and depression-like behavior in mouse models. Scheich B., Gaszner B., Kormos V., Laszlo K., Adori C., Borbely E., Hajna Z., Tekus V., Bolcskei K., Abraham I., Pinter E., Szolcsanyi J., Helyes Z.
Neuropharmacology (2016/101: 204-215. )
DOI | PubMed | Scopus

(2016-2020): PEPSYS GINOP-2.3.2-15-2016-00050 – “Complexity of peptidergic signalization and its role in systemic diseases”

(2017-2020): EFOP-3.6.2 “Investigation of neuroinflammatory and neurodegenerative mechanisms from the molecule to bedsite”

(2015-2017): NKFIH-OTKA-NN-114458 “Investigation of TRP channel-mediated effects of hydrogen sulfide in animal models of acute and chronic arthritis”

(2017-2018) Richter Témapályázat RG-IPI-2016-TP10/042

“A TRPA1 receptor, mint potenciális gyógyszercélpont az Alzheimer-kór kezelésében”

(2017-2020) EFOP-3.6.2-16-2017-00006 LIVE LONGER „Modern orvostudományi diagnosztikus eljárások és terápiák fejlesztése transzlációs megközelítésben: a laboratóriumtól a betegágyig"

(2017-2020) STAY ALIVE GINOP-2.3.2-15-2016-00048 – “Excellence of R+D Strategic Centres: Improving the severity and lethality parameters of life-threatening diseases from a translational approach”

(2017-2020) NAP-2 “TRPA1 receptor as a potential drug target in neuroinflammation and neurodegenerative disorders”